Gritgen Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese gene therapy biotech developing next-generation AAV-based treatments for rare and common diseases, with a lead hemophilia A program in Phase I trials.
HematologyRare DiseaseGenetics
Technology Platform
Proprietary next-generation AAV capsid platform combined with high-efficiency promoter and enhancer systems for improved gene therapy vector design and delivery.
Opportunities
Large addressable markets in hemophilia and other genetic diseases in China, potential to expand pipeline using proprietary AAV platform technology to additional indications.
Risk Factors
Clinical development risks for lead program GS1191, competitive landscape in hemophilia gene therapy, and dependence on future funding as a private, pre-revenue company.
Competitive Landscape
Competes with global hemophilia gene therapy developers like BioMarin (Roctavian) and Pfizer/Sangamo (giroctocogene fitelparvovec), plus Chinese gene therapy companies, differentiating through proprietary AAV capsid and regulatory element technology.